Table 10.
Frequencies (number of dogs and percentages) or medians (interquartile range) of laboratory variables measured at D84 in the 2 treatment groups (i.e, on 273 dogs that ended the study).a
| Variable | Treatment group | |||
|---|---|---|---|---|
| Torasemide n = 133 | Furosemide n = 140 | P‐value | ||
| Serum K (mmol/L) | 4.30 [3.80–4.70] | 4.50 [4.20–5.00] | 0.0027 | |
| Serum creatinine (mg/L) | 12.10 [9.40–15.90] | 9.85 [8.20–13.60] | 0.0015 | |
| Global score | IRIS stage: 1/2/3/4 (%) | 86/32/15/0 (65/24/11/0) | 109/22/8/1 (78/16/6/1) | 0.041 |
| Study 1 | IRIS stage: 1/2/3/4 (%) | 39/12/6/0 (68/21/11/0) | 43/7/1/0 (84/14/2) | 0.098 |
| Study 2 | IRIS stage: 1/2/3/4 (%) | 47/20/9/0 (62/26/12/0) | 66/15/7/1 (74/17/8/1) | 0.22 |
IRIS, International Renal Interest Society; K, potassium.
Out of the 366 dogs included in the trial, 93 dogs did not end the study, owing to 24 cardiac deaths (composite cardiac endpoint), 4 additional cardiac deaths after CHF worsening, 20 non cardiac deaths, 38 withdrawals for adverse events, and 7 withdrawals following owners' wishes.
Laboratory reference ranges: serum K = 3.90–5.60 mmol/L; serum creatinine = 4.00–12.00 mg/L.
P‐values that appear in bold are < 0.05.